Role of metallothionein 3 in diabetic nephropathy via interplay with HIF-1α.

Yuri Takiyama, Yumi Takiyama, Takao Takiyama, Ryoichi Bessho, Hiroya Kitsunai, Akira Takasawa, Hiroshi Nomoto

Abstract read

In one paragraph

Article in Diabetology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Specificity of endothelial cells in endothelial dysfunction of diabetic kidney disease and their crosstalk with neighboring cells: an updated review.Frontiers in endocrinology · 2025
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuri TakiyamaDivision of Endocrinology, Metabolism and Rheumatology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510 Japan.

Yumi TakiyamaDivision of Endocrinology, Metabolism and Rheumatology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510 Japan.ORCID 0000-0002-7443-7817

Takao TakiyamaDivision of Endocrinology, Metabolism and Rheumatology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510 Japan.

Ryoichi BesshoDivision of Endocrinology, Metabolism and Rheumatology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510 Japan.

Hiroya KitsunaiDivision of Endocrinology, Metabolism and Rheumatology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510 Japan.

Akira TakasawaDivision of Tumor Pathology, Department of Pathology, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510 Japan.

Hiroshi NomotoDivision of Endocrinology, Metabolism and Rheumatology, Department of Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa, 078-8510 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metallothioneins (MTs) are a cysteine-rich protein that scavenges reactive oxygen species. Hypoxia is involved in the progression of diabetic nephropathy (DN) and aggravates oxidative stress. Hypoxia dramatically induced Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-025-00840-y.

Indexed as

Diabetic nephropathyHIF-1HypoxiaMetallothionein 3

Identifiers

PMID41111571

DOI10.1007/s13340-025-00840-y

PMCPMC12532810

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.